Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Mohamed Abou-el-Enein Clear advanced filters

  • Base and prime editors extend the therapeutic scope of genome editing. Experience from CRISPR clinical trials offers a roadmap for their translation, from manufacturing and quality control to clinical trial design and regulatory assessment.

    • Christian L. Flugel
    • Amaia Cadinanos-Garai
    • Mohamed Abou-el-Enein
    Comments & Opinion
    Nature Reviews Bioengineering
    P: 1-3

  • Chimeric antigen receptor (CAR) T cells are effective therapies for patients with relapsed and/or refractory B cell malignancies, partly owing to the ability to target B cell-specific antigens. However, CAR T cells targeting solid tumour antigens are likely to carry a higher risk of on-target, off-tumour toxicity (OTOT). Here, the authors summarize the available data on OTOT in the context of CAR T cells targeting solid tumour antigens and describe novel CAR T cell designs that might overcome such toxicities.

    • Christian L. Flugel
    • Robbie G. Majzner
    • Mohamed Abou-el-Enein
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 20, P: 49-62

  • Chimeric antigen receptor T cells have revolutionized the treatment of patients with certain haematological malignancies. Nonetheless, an optimal approach to lymphodepleting chemotherapy and/or bridging therapies has yet to be defined in patients receiving these agents. In this Review, the authors describe the various lymphodepletion and/or bridging therapy strategies used, and highlight the need for prospective comparisons in order to determine the safest and most effective approach.

    • Leila Amini
    • Sara K. Silbert
    • Mohamed Abou-el-Enein
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 19, P: 342-355

  • The T cell receptor β-chain is expressed in two isoforms, TRBC1 and TRBC2, with clonally expanded mature T cell lymphomas expressing one of them exclusively, while healthy T cells randomly express either TRBC1 or TRBC2. Here authors show structure-based design of a TRBC2-specific antibody, and depletion of malignant T cells carrying TRBC1 or TRBC2 with CAR-T cells against the cognate receptor chain in murine models.

    • Mathieu Ferrari
    • Matteo Righi
    • Martin Pule
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-16

  • CD19-specific chimeric antigen (CAR)-modified T cells are approved for patients with advanced-stage forms of certain B cell malignancies. However, a subset of patients will have anti-CAR immune responses, leading to a lack of CAR T cell persistence and a rapid loss of any antitumour efficacy. In this Review, the authors describe the extent of anti-CAR immune responses in patients and suggest measures that could be used to better monitor for these events. Additionally, they describe novel approaches to CAR T cell therapy that might reduce the risk of such responses in the future.

    • Dimitrios L. Wagner
    • Enrico Fritsche
    • Mohamed Abou-el-Enein
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 18, P: 379-393